1.The changes of the glycolipid and coronary artery lesions in coronary artery disease patients with isolated post-challenge hyperglycaemia
Wenyan LIU ; Fangyu XIE ; Yumei LI
Chinese Journal of Practical Nursing 2016;32(29):2250-2253
Objective To observe the changes of the glycolipid and coronary artery lesions in coronary artery disease patients with isolated post-challenge hyperglycaemia (IPH). Methods Hospitalized coronary artery disease patients diagnosed by coronary angiography were received oral glucose tolerance test. The labarotary test datas, including blood hematochrome, fasting and post-challenge plasma glucose levels, plasma lipid and insulin levels, were recorded. The number of diseased coronary artery and coronary lesion scores were calculated according to coronary angiogram for each patient. Continuous 77 patients with normal glucose metabolism(normal glucose metabolism group) and 104 patients with IPH (IPH group) entered the study. Results The occurrence of hypertension, acute coronary syndrome, multivessel coronary disease, revascularization were 84.6%(88/104), 82.7%(86/104), 69.2%(72/104), 70.2%(73/104) in IPH group and 63.6%(49/77), 70.1%(54/77), 50.6%(39/77), 54.5%(42/77) in normal glucose metabolism group, and there were significant differences(χ2=3.985-10.583, all P<0.05). The body mass index, triglyceride, total cholesterol, fasting glucose, post-challenge glucose, hemoglobin A1c, fasting insulin, insulin resistance index, coronary lesion scores were (27.42±3.55) kg/m2,(2.18±1.53) mmol/L,(4.73 ± 1.00) mmol/L,(5.98 ± 0.92) mmol/L, (14.11 ± 1.94) mmol/L, (5.90 ± 0.78)%, (10.07 ± 6.13) mU/L, 2.617 ± 1.535, (41.35 ± 27.21) points in IPH group and (25.11 ± 3.40) kg/m2, (1.52 ± 0.85) mmol/L, (4.22 ± 1.02) mmol/L, (5.24±0.62) mmol/L, (6.49±1.07) mmol/L, (4.97±0.39)%, (7.72±4.28) mU/L,1.785±0.974, (33.36±23.36) points in normal glucose metabolism group, and there were significant differences(t=3.035-33.698, P<0.05 or 0.01). Conclusions Coronary artery disease patients with IPH have much more seriously abnormal glycolipid metabolism and complex coronary artery lesions, and need specialized nursing management.
2.Effects of nutrition guidance on energy intake and body weight of patients with gastric cancer for the first time chemotherapy
Fenglan XIE ; Fangyu LIN ; Lifen PENG ; Zhuoqin JIANG
Chinese Journal of Practical Nursing 2016;32(23):1813-1816
Objective To investigate the effect of nutritional guidance on the energy intake and body weight of patients with gastric cancer chemotherapy. Methods The experimental study was used to study the 144 cases with gastric cancer for the first time of chemotherapy. They were randomly divided into the experimental group and the control group, 72 cases in each group. Routine healthy guidance was used in the control group, while the patients in the experimental group were treated by the nutrition prescription, the nutrition guidance, the purpose and the significance of the chemotherapy, and the follow-up of the patients after discharge. The body weight of patients was collected before chemotherapy, and the dietary questionnaire was used for second days after first days of dietary intake, and the changes of energy consumption and body weight were compared between the two groups. Results The mean values of energy intake within 24 hours in the first 3 days after the chemotherapy in the experimental group was 5 068.92 kJ, which was 51%of the RNI. The mean values of energy intake within 24 hours in the first 3 days after the chemotherapy in the control group was 3 439.25 kJ, which was 38%of the RNI. The difference between the two groups was significant (P<0.01). The weight of patients in the experimental group at the time point of before the 5th and 6th time of chemotherapy were significant higher than those in the control group (P<0.05). Energy intake had influenced the patients′weight, high energy intake with low decrease of body weight. Conclusions Nutritional guidance can effectively improve the energy intake of patients with gastric cancer when chemotherapy, so that the weight remained stable during chemotherapy.
3.Construction and implementation of the "Internet+nursing service" model based on the nurse-patient safety needs
Fenglan XIE ; Fangyu LIN ; Siqi ZHU ; Shouzhen CHENG
Chinese Journal of Practical Nursing 2023;39(3):188-194
Objective:To explore the "Internet + nursing service" model based on the nurse-patient safety needs, and provide reference for development of "Internet + nursing service".Methods:The First Affiliated Hospital of Sun Yatsen University established a "Internet+ nursing service" management team in December 2019, developed an information platform, formulated and implemented a specific plan of the "Internet+ nursing service" model, including service objects, service projects and service modes. After the smooth operation of this model, the statistics of the nursing service projects and service times that had been carried out from September 2020 to March 2021, as well as the satisfaction of 21 patients who received nursing services would be counted.Results:From September 2020 to March 2021, 21 patients were provided with 55 on-site nursing services, and 151 operations in 16 projects were completed. No nursing-related adverse events occurred. The patients gave all five-star evaluations to the door-to-door service, the satisfaction score was 5 points, and the overall evaluation was 99.88 points.Conclusions:The pilot work of "Internet + nursing service" based on the nurse-patient safety needs has met the care needs of discharged patients and the safety needs of door-to-door services, guarantee the safety of nurses' door-to-door service effectively. And it provides reference for the development and improvement of "Internet + nursing service" related safety work in tertiary A-level hospitals.
4.Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in lymph node metastases and risk stratification of endometrial carcinoma
Dou dou LIU ; Jianfang LI ; Xiaomao LI ; Liangjun XIE ; Luping QIN ; Fangyu PENG ; Mu hua CHENG
Journal of Gynecologic Oncology 2019;30(6):e89-
OBJECTIVE: To investigate the prognostic value of metabolic tumor volume (MTV) and total lesion glycolysis (TLG), measured by preoperative ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT), in risk stratification of patients with endometrial carcinoma (EC). METHODS: The patients with pathological diagnosis of EC who underwent preoperative ¹⁸F-FDG PET/CT imaging were retrospectively selected for analysis of the prognostic values of PET parameters in risk classification and lymph node metastases (LNMs). Receiver-operating-characteristic analysis was used to analyze the correlation of PET parameters cutoff values with deep myometrial invasion (MI), lymphovascular space involvement and LNM for prognostic values in risk stratification. RESULTS: The sensitivity, specificity, positive predictive value, negative predictive value and accuracy for detection of LNM are 83.3%, 99.7%, 90.9%, 99.5% and 99.2%, respectively. The MTV and TLG of primary lesion of EC in the patients with LNM are notably higher than those in patients without LNM, p<0.010. The MTV and TLG of the EC primary lesions in high-risk patients are significantly higher than those in low-risk patients (p<0.010), but the maximum standardized uptake value (SUVmax) is not. The MTV and TLG of primary lesions were superior to SUVmax for predicting of deep MI, LNM and high-risk of EC (p<0.005). CONCLUSION: MTV and TLG of primary lesions are more valuable in predicting risk stratification of EC patients. Preoperative ¹⁸F-FDG PET/CT imaging is useful in predicting the LNM of EC and may help guide pelvic lymphadenectomy to avoid unnecessary pelvic lymphadenectomy in EC patients with low-risk stratification.
Classification
;
Diagnosis
;
Electrons
;
Endometrial Neoplasms
;
Female
;
Glycolysis
;
Humans
;
Lymph Node Excision
;
Lymph Nodes
;
Lymphatic Metastasis
;
Metabolism
;
Neoplasm Metastasis
;
Positron-Emission Tomography and Computed Tomography
;
Retrospective Studies
;
Risk Assessment
;
Sensitivity and Specificity
;
Tumor Burden
5.Expression of serum miR-224-5p in pancreatic ductal adenocarcinoma and its significance in early diagnosis
Xiaojuan JIA ; Weiwei ZHANG ; Wenli LI ; Dalei JIANG ; Fangyu XIE ; Yi ZHANG ; Lailin FU ; Yao WANG ; Bin CHEN ; Min SONG ; Jing LI ; Xiangjun XIE
Chinese Journal of Pancreatology 2020;20(6):412-417
Objective:To explore the expression of serum miR-224-5p in PDAC and its significance for early clinical diagnosis.Methods:From August 2018 to April 2020, 40 patients with PDAC (11 patients with early PDAC, 29 patients with advanced PDAC), 21 patients with chronic pancreatitis and 40 healthy volunteer controls admitted in Qingdao Municipal Hospital were enrolled. The level of serum miR-224-5p in each group was detected by qRT-PCR method, and the correlation with clinicopathological parameters was analyzed. The receiver-operating characteristic (ROC) curve of miR-224-5p, CA19-9 and miR-224-5p combined with CA19-9 were drawn, and the sensitivity and specificity of the diagnosis were calculated.Results:The serum miR-224-5p levels in early PDAC group, middle and late PDAC group, chronic pancreatitis group and healthy control group were 3.21(2.01, 4.60), 4.70(3.50, 8.26), 1.72(1.02, 2.78) and 1.38(0.89, 2.11), respectively; and the level of serum miR-224-5p in the middle and late PDAC group was significantly higher than that in the early PDAC group, and that in the early PDAC group was significantly higher than that in the chronic pancreatitis group and the healthy control group, and all the differences were statistically significant ( P<0.05). The sensitivity of serum miR-224-5p combined with CA19-9, miR-224-5p, and CA19-9 in the diagnosis of overall PDAC was 95.0%, 85.0% and 67.5%, respectively; and the specificity was 70.0%, 82.5% and 87.5%, respectively. The sensitivity for early PDAC was 90.9%, 72.7% and 63.6%, and the specificity was 85.0%, 72.5% and 87.5%, respectively. MiR-224-5p combined with CA19-9 has the highest specificity in the diagnosis of PDAC. The level of serum miR-224-5p in patients with PDAC was correlated with TNM stage, lymph node metastasis and distant metastasis (all P values <0.05). Conclusions:The expression of serum miR-224-5p was significantly up-regulated in patients with early PDAC, and The level of serum miR-224-5p in patients with PDAC was correlated with TNM stage, lymph node metastasis and distant metastasis. The sensitity of serum miR-224-5p and miR-224-5p combined with CA19-9 for early PDAC diagnosis were superior to CA19-9 alone, which can be used as a potential sensitive biological marker for early screening of PDAC.
6. Advances in development of 64CuCl2 radiotracer for diagnostic imaging of copper metabolism disorders with PET
Huawei CAI ; Fang XIE ; Fangyu PENG
Chinese Journal of Nuclear Medicine and Molecular Imaging 2019;39(6):370-373
Development of new radiopharmaceuticals is crucial for the advance of nuclear medicine and molecular imaging. In recent years, significant progress has been made in the development of radiopharmaceuticals based on radioactive metal nuclides such as 64Cu. Copper is a transition metal element necessary for human physiology. Disorders of copper metabolism not only cause hereditary Wilson disease and Menkes disease, but also play an important role in the development of malignant tumors. In addition to radiolabeling for probes, 64Cu can be used for PET diagnostic imaging of copper metabolism disorders. 64CuCl2 is a useful radiotracer that can be used to track the dynamic flow of copper ions in human body copper metabolism by PET imaging. In recent years, many preclinical and clinical studies of 64CuCl2 radiotracer have achieved good results, and have attracted a lot of attention in the field of nuclear medicine and molecular imaging. In this article, the progress in the development of 64CuCl2 as a radiotracer for PET diagnostic imaging of hereditary copper metabolism disorders and copper hypermetabolic tumors is reviewed, and further research studies and potential clinical application of 64CuCl2 PET/CT imaging is prospected.
7.Value of serum miR-486-5p combined with carbohydrate antigen 19-9 in predicting resectable or borderline resectable pancreatic cancer
Yi ZHANG ; Weiwei ZHANG ; Fangyu XIE ; Wenli LI ; Dalei JIANG ; Xiaojuan JIA ; Lailin FU ; Yao WANG ; Bin CHEN ; Min SONG ; Lisha JI ; Xiangjun XIE
Journal of Clinical Hepatology 2021;37(10):2400-2404
Objective To investigate the expression level of serum miR-486-5p in patients with pancreatic cancer and the value of serum miR-486-5p combined with carbohydrate antigen 19-9 (CA19-9) in predicting the resectability of pancreatic cancer. Methods A total of 60 patients who were diagnosed with pancreatic cancer in Qingdao Municipal Hospital from September 2018 to December 2020 were enrolled, among whom 32 patients had resectable or borderline resectable pancreatic cancer (operable group) and 28 had unresectable pancreatic cancer (non-operable group), and a benign pancreatic disease group with 30 patients and a healthy control group with 44 individuals were also established. Quantitative real-time PCR was used to measure the serum level of miR-486-5p in each group, and the relative expression level of miR-486-5p was calculated to analyze its association with the clinical features of pancreatic cancer, including age, sex, tumor location, tumor size, TNM stage, lymphatic metastasis, and distant metastasis. The Mann-Whitney U test was used for comparison of non-normally distributed continuous variables between two groups, and the chi-square test was used for comparison of categorical variables. The receiver operating characteristic (ROC) curve was plotted, and a binary logistic regression analysis was used to calculate the combined predictive value and then investigate the value of serum miR-486-5p combined with CA19-9 in predicting the resectability of pancreatic cancer. Results The relative expression level of serum miR-486-5p in the operable group [2.16 (1.38~3.30)] and the non-operable group [4.65 (2.80~9.90)] was significantly higher than that in the benign pancreatic disease group [1.01 (0.52~1.53)] and the healthy control group [0.99 (0.24~1.01)] (all P < 0.001). There were significant differences in the number of patients with low or high expression of miR-486-5p between the patients with different TNM stages, presence or absence of lymphatic metastasis, and presence or absence of distant metastasis ( χ 2 =13.765, 5.157, and 6.638, all P < 0.05). Compared with CA19-9 alone, miR-486-5p+CA19-9 had a significantly better value in distinguishing the operable group from the benign pancreatic disease group (area under the ROC curve [AUC]=0.87, 95% confidence interval [ CI ]: 0.760-0.942; with a sensitivity of 81.3% and a specificity of 83.3%), distinguishing the operable group from the healthy control group (AUC=0.92, 95% CI : 0.836-0.970; with a sensitivity of 90.6% and a specificity of 86.4%), and distinguishing the operable group from the non-operable group (AUC=0.94, 95% CI : 0.884-0.998; with a sensitivity of 85.7% and a specificity of 93.7%) ( Z =2.841, 2.510, and 2.387, all P < 0.05), and the optimal cut-off values were 3.12, 3.21, and 6.63, respectively. Conclusion MiR-486-5p can be used as a serum biomarker for the diagnosis of pancreatic cancer, and miR-486-5p combined with CA19-9 has a better clinical value than CA19-9 alone in predicting the resectability of pancreatic cancer in the patients with benign pancreatic diseases and the healthy population.